Psychosocial treatment of needle phobia in children

aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress

Retrieved on: 
星期一, 四月 3, 2023
Vaccine, Antigen, CSO, Needle, Vaccine hesitancy, Psychosocial treatment of needle phobia in children, Congress, Tetanus, WVC, Anthrax, Syringe

OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA.

Key Points: 
  • OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA.
  • The company will present a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models”.
  • The immunogenicity data from four in vivo models reinforces the value of the company’s needle-free solid-dose vaccine platform as a novel way to effectively deliver vaccines for tetanus, anthrax, influenza, and peanut allergy.
  • Dr Keith Howard, aVaxziPen’s CSO, said, “With our needle-free technology we’re on a mission to transform vaccine delivery for the benefit of communities around the world.

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Retrieved on: 
星期四, 二月 23, 2023
Patient, Allergy, ARS-1, PD, American Academy of Allergy, Asthma, and Immunology, Adrenaline, OTC, Research, ARS, Emergency, NDA, AAAAI, New Drug Application, Dislike (film), Prescription, Asthma, Psychosocial treatment of needle phobia in children, Failure, Caregiver, Anaphylaxis, American Academy, Pharmaceutical industry, Generic drug

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of allergic reactions (Type I), including anaphylaxis, will be presented during the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) meeting. The meeting is being held February 24-27, 2023, in San Antonio, Texas.

Key Points: 
  • The meeting is being held February 24-27, 2023, in San Antonio, Texas.
  • “We are excited to share these data from two of our primary clinical trials and the integrated analysis demonstrating the performance of neffy.
  • Patients indicated they would be more likely to fill a prescription for a needle-free device versus an epinephrine autoinjector.
  • A majority of patients indicated they would use a needle-free device instead of or before an OTC product.

Canadian Company PKA SoftTouch has achieved the first significant revolution in syringes in 170 years with pain-free Micro-Needle

Retrieved on: 
星期三, 十月 26, 2022
University, Human, PKA, Diabetes, Injection, World Health Organization, Psychosocial treatment of needle phobia in children, Medtech, Syringe, Communication, Patient, Technology, World, Quality of life, GLOBE, Population, WHO, Animal, Pharmaceutical industry, Vaccine

PKA SoftTouch reimagines the concept of injection entirely, with no pain, easy use, and no sharp disposal needed.

Key Points: 
  • PKA SoftTouch reimagines the concept of injection entirely, with no pain, easy use, and no sharp disposal needed.
  • The revolutionary PKA SoftTouch Micro-Needle has shown that a shallow delivery process enhances uptake, bioavailability, and efficacy of drugs, when compared to conventional deep muscular methods of syringe injection.
  • PKA SoftTouch Corp. is a leading-edge research and development company that has created a unique, revolutionary and proprietary device; the PKA SoftTouch Micro-Needle.
  • The PKA SoftTouch Micro-Needle meets the need for humans and animals to receive lifesaving drugs in a painless, safe, inexpensive, and simple manner.